Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Canada / NCT07487792
Starting soon Not applicable

Feasibility of Imaging Breast Implants With a Transmission-based Microwave Scanner

NCT07487792 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2026-09-15
Last updated
2026-06-25

Condition(s) studied

Breast - Female

Investigational drug(s) / intervention(s)

WVI-MIS-03-2025

WVI-MIS-03-2025: Microwave scans

Study summary

The goal of this clinical trial is to assess whether microwave scans can depict the presence of implants in the breast in women with existing breast implants that were surgically placed at least 6 months ago. The main questions it aims to answer are:

1. Can a microwave imaging device effectively scan a breast containing implants?
2. Can the presence of implants be identified in a microwave scan?
3. Can the microwave scans of the left and right breasts be compared to assess whether similarity is observed?

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Women with breast implants placed at least 6 months prior who are asymptomatic for implant rupture as well as those with known implant rupture * Female * Minimum of 18 years of age * Able to provide informed consent Exclusion Criteria: * Women who are currently pregnant or breastfeeding * Women with active breast infections * Women with nipple piercings (unless removed prior to scanning) * Women with implanted electronic device * Women with physical limitations that prevent them from placing their breasts inside the scanner

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Demsey Plastic Surgery Clinic Calgary Alberta

More University of Calgary trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07487792 on ClinicalTrials.gov ↗ ← All trials in Canada